In the multivariable Cox proportional hazards regression analysis accounting for potential confounders, rituximab demonstrated a higher risk (HR, 1.91; 95% CI, 1.17-3.14) of any incident cancer compared with TNFis, followed by abatacept (HR, 1.47; 95% CI, 1.03-2.11) and JAKis (HR, 1.36; 95% CI, 0.94-1.96) (Table 2; Figure 3).16,17,18 Interleukin 6 inhibitors exposures had a similar risk of incident cancer as TNFis (HR, 1.04; 95% CI, 0.57-1.92). This evidence concerns the gene IL6 and cancer.